BNP Paribas Asset Management
DNLI icon

BNP Paribas Asset Management’s Denali Therapeutics DNLI Stock Holding History

BNP Paribas Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.69M Sell
296,503
-2,289
-0.8% -$45.5K 0.01% 831
2025
Q4 		$4.93M Buy
298,792
+297,521
+23,408% +$5.02M 0.01% 846
2025
Q3 		$18K Buy
1,271
+132
+12% +$1.9K ﹤0.01% 1427
2025
Q2 		$16K Buy
+1,139
New +$16K ﹤0.01% 1592

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Asset Management's DNLI Position: Q1 2026 in Review

BNP Paribas Asset Management reduced its Denali Therapeutics (DNLI) stake by 0.77% in Q1 2026, selling an estimated $45.5K and leaving 296,503 shares worth $5.69M. The position accounts for 0.01% of the portfolio, ranked #831.

BNP Paribas Asset Management first reported a position in DNLI in Q2 2025 and has held it in 4 quarters since. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • BNP Paribas Asset Management held 296,503 shares of Denali Therapeutics worth $5.69M as of Q1 2026.
  • BNP Paribas Asset Management sold 2,289 Denali Therapeutics shares in Q1 2026, an estimated $45.5K.
  • Denali Therapeutics made up 0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #831 holding.
  • BNP Paribas Asset Management first reported a position in Denali Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.